Publications & Posters
Scholarly publications
Immuno-Oncology
SRK-181
March 2020
Science Translational Medicine
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
Spinal Muscular Atrophy
Apitegromab
March 2020
MDA Clinical and Scientific Conference
A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction
Spinal Muscular Atrophy
Apitegromab
February 2020
SMA Europe
A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction
Spinal Muscular Atrophy
Apitegromab
February 2020
SMA Europe
Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
October 2019
World Muscle Society Congress
SRK-015, a Fully Human Monoclonal Antibody Inhibiting Myostatin Activation, Offers Sustained Target Engagement Across Multiple Species, Including Humans
Spinal Muscular Atrophy
Apitegromab
July 2019
SLAS Discovery
